Humacyte (HUMA) said Monday that its Symvess acellular tissue-engineered vessel achieved an 87.1% patency rate, 100% limb salvage, and zero conduit infections for up to 18 months in vascular trauma patients.

The company said 17 Ukrainian patients with battlefield extremity injuries were treated with Symvess in a real-world combat setting, with up to 18 months of follow-up.

Humacyte said there were "zero deaths, zero infections, and zero amputations" at up to 18 months of follow-up. There were also no cases of immunological rejection, the company added.

The results were published in Oxford Academic's Military Medicine Journal, Humacyte said.

The company's shares were up more than 8% in recent premarket activity Monday.